The global Postpartum Depression Drug Market is estimated to be valued at US$ 6.638 Billion In 2022 and is expected to exhibit a CAGR of 30.25%
Postpartum Depression Drug Market |
The
global Postpartum Depression Drug Market is estimated to be valued at US$ 6.638 Billion In 2022 and is
expected to exhibit a CAGR of 30.25%
over the forecast period 2022-2029, as highlighted in a new report published by
Coherent Market Insights.
Market Overview:
Postpartum depression drugs help reduce depressive symptoms such as sadness,
anxiety, guilt, mood swings, trouble sleeping and lack of energy that arise
after childbirth. These drugs act on neurotransmitters like serotonin and
norepinephrine in the brain to alleviate symptoms. Regular intake is needed for
continuous management of the condition.
Market key trends:
One of the key trends fuelling the postpartum depression drug market growth is
the increasing awareness about the condition and the availability of treatment
options. Several governments and non-profit organizations conduct seminars and
awareness programs to educate women and their families about postpartum
depression. They explain common symptoms, impact of the condition as well as
safe treatment options using antidepressants. This is encouraging more women to
seek medical help timely.
Here is the segment analysis and key takeaways for the given Postpartum
Depression Drug market research report:
Segment Analysis
The global Postpartum
Depression Drug Market is segmented based on drugs, distribution
channel, and region. By drugs, the selective serotonin reuptake inhibitors
(SSRIs) sub-segment dominates the market and accounted for around 65% of market
share in 2021. SSRIs are commonly prescribed for postpartum depression as they
are considered relatively safe and have fewer side effects compared to other
antidepressants.
Key Takeaways
The global postpartum depression drug market size was valued at US$ 5.115 Billion In 2021 and is
expected to witness high growth, exhibiting a CAGR of 30.25% over the forecast period from 2022-2029. The growth
is attributed to increasing awareness about postpartum depression and the
availability of various treatment options.
Regional analysis shows that North America dominated the global market in 2021
with a share of around 45%, followed by Europe. This is owing to early adoption
of advanced drugs, stringent regulatory guidelines for marketing authorization
of new drugs, and established healthcare infrastructure in the regions.
However, Asia Pacific is expected to witness the highest CAGR during the
forecast period due to improving healthcare facilities and growing disposable
income in developing countries such as China and India.
Key players operating in the postpartum depression drug market include Sage
Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas
Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co.,
Ltd. Among them, Sage Therapeutics Inc. holds the largest market share owing to
its innovative drug pipeline for treating postpartum depression.
Read More : https://www.rapidwebwire.com/postpartum-depression-drug-market-outlines-promising-growth/
Comments
Post a Comment